2,843
Views
3
CrossRef citations to date
0
Altmetric
Research Paper

Safety and Immunogenicity of a novel three-dose recombinant nanoparticle rabies G protein vaccine administered as simulated post exposure immunization: A randomized, comparator controlled, multicenter, phase III clinical study

, , , , , , , & ORCID Icon show all
Pages 4239-4245 | Received 12 May 2021, Accepted 12 Jul 2021, Published online: 09 Sep 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Anurag Agarwal & Surendra Bahadur Mathur. (2022) Letter to the editor: Safety and immunogenicity of a novel recombinant rabies vaccine. Human Vaccines & Immunotherapeutics 18:5.
Read now

Articles from other publishers (2)

Charles E. Rupprecht, Philip P. Mshelbwala, R. Guy Reeves & Ivan V. Kuzmin. (2023) Rabies in a postpandemic world: resilient reservoirs, redoubtable riposte, recurrent roadblocks, and resolute recidivism. Animal Diseases 3:1.
Crossref
Luis Giovani Oliveira Guardalini, Paulo Eduardo da Silva Cavalcante, Jaci Leme, Renata Gois de Mello, Thaissa Consoni Bernardino, Renato Mancini Astray, Aldo Tonso, Soraia Attie Calil Jorge & Eutimio Gustavo Fernández Núñez. (2023) Oxygen uptake and transfer rates throughout production of recombinant baculovirus and rabies virus-like particles. Process Biochemistry 124, pages 189-200.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.